Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis CECT 8145
- Development stage
- Unknown
- Lead developer
- Archer Daniels Midland
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis CECT 8145 (also known as BPL1) is a specific probiotic strain developed by Biopolis (now part of ADM) for the management of obesity and metabolic disorders. It is available in both live (probiotic) and heat-killed (postbiotic) forms. The strain was originally identified through high-throughput screening in *Caenorhabditis elegans* for its ability to reduce fat deposition. In human clinical trials, CECT 8145 has demonstrated efficacy in reducing visceral fat, body mass index (BMI), and waist circumference in abdominally obese individuals, particularly women. It has also been studied in children with Prader-Willi Syndrome, where it improved abdominal adiposity, insulin sensitivity, and certain mental health symptoms. The mechanism of action involves modulation of the gut microbiome (notably increasing *Akkermansia* species) and enhancement of the insulin/IGF-1 signaling pathway, potentially mediated by its cell wall component, lipoteichoic acid.
- Brand names
- BPL1BPL-1BPL 1
- Other names
- Bifidobacterium animalis subsp. lactis strain BPL1Bifidobacterium animalis subsp. lactis strain CECT 8145
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis CECT 8145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis CECT 8145.